Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Association Between Dietary Factors and Chronic Subdural Hematoma: a Multicenter Case-control Study
Authors not listed
Beijing Tiantan Hospital · 2023
Abstract
A prospective, multicenter, case control trial is designed to compare difference in dietary and nutritional factors in patients with and without chronic subdural hematoma.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-10-16 MST
Cite this
APA
Anonymous. (2023). Association Between Dietary Factors and Chronic Subdural Hematoma: a Multicenter Case-control Study. <em>Beijing Tiantan Hospital</em>. https://clinicaltrials.gov/study/NCT05599217
Vancouver
Anonymous. Association Between Dietary Factors and Chronic Subdural Hematoma: a Multicenter Case-control Study. Beijing Tiantan Hospital. 2023.
BibTeX
@misc{anon2023Associ,
title = {Association Between Dietary Factors and Chronic Subdural Hematoma: a Multicenter Case-control Study},
author = {Anonymous},
journal = {Beijing Tiantan Hospital},
year = {2023},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Region Skane 2020
Open access · US-GOV
ACUTE-Acute Surgical Care- Risk Factors and Outcomes for Patients in Need of Acute Surgical Care
Medivation, Inc. 2009
Open access · US-GOV
CONTACT: A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Six-Month Safety and Efficacy Study of Dimebon in Patients With Moderate-to-Severe Alzheimer's Disease
Intensive Care Medicine 2014
Preprint · OA
Prevalence and impact of frailty on mortality in elderly ICU patients: a prospective, multicenter, observational study
Vigil Neuroscience, Inc. 2023
Open access · US-GOV
A Phase 1, First-in-human, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study in Healthy Adults and Open-label Single Dose Study in Patients With Alzheimer's Disease to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VG-3927
Medesis Pharma SA 2022
Open access · US-GOV
Prospective, Multicenter, First Part Randomized, Placebo-controlled, Parallel-group, Double-blind Period Followed by Open-label Trial Period to Evaluate Clinical Safety & Efficacy of NanoLithium® NP03 in Patients With Mild-to-severe Alzheimer's Disease: Proof-of-concept Study
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University 2026
Open access · US-GOV